Dr. Efebera is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
500 Thomas Ln
Columbus, OH 43214Phone+1 614-566-2500Fax+1 614-293-4812
Education & Training
- Boston University Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
- Cleveland Clinic FoundationResidency, Internal Medicine, 1998 - 2001
- Pennsylvania State University College of MedicineClass of 1998
Certifications & Licensure
- OH State Medical License 2000 - 2025
- TX State Medical License 2008 - 2022
- MA State Medical License 2004 - 2014
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
- Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis Start of enrollment: 2010 Nov 01
- Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Start of enrollment: 2011 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 168 citationsAutologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 TrialEdward A. Stadtmauer, Marcelo C. Pasquini, Beth Blackwell, Parameswaran Hari, Asad Bashey
Journal of Clinical Oncology. 2019-01-17 - 41 citationsT Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.Fabienne Lucas, Michael L. Pennell, Ying Huang, Don M. Benson, Yvonne A. Efebera
Biology of Blood and Marrow Transplantation. 2020-01-01 - 130 citationsThree prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maravir...Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, Mingwei Fei, Sunil Abhyankar
The Lancet. Haematology. 2019-03-01
Abstracts/Posters
- The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL AmyloidosisYvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional ExperienceYvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- OhioHealth's New Blood and Marrow Transplant Program Is OpenApril 5th, 2022
- What Is the Optimal Duration of Maintenance in Myeloma?October 8th, 2019
- Late-Breaking Abstracts SessionDecember 6th, 2016
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: